Achilles Therapeutics Plc ADR (ACHL) concluded trading on Thursday at a closing price of $1.42, with 4.31 million shares of worth about $6.12 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 98.60% during that period and on March 13, 2025 the price saw a gain of about 2.16%. Currently the company’s common shares owned by public are about 41.10M shares, out of which, 37.95M shares are available for trading.
Stock saw a price change of 2.16% in past 5 days and over the past one month there was a price change of 2.90%. Year-to-date (YTD), ACHL shares are showing a performance of 24.56% which increased to 15.45% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.63 but also hit the highest price of $1.41 during that period. The average intraday trading volume for Achilles Therapeutics Plc ADR shares is 1.18 million. The stock is currently trading 2.43% above its 20-day simple moving average (SMA20), while that difference is up 11.12% for SMA50 and it goes to 41.94% higher than SMA200.
Achilles Therapeutics Plc ADR (NASDAQ: ACHL) currently have 41.10M outstanding shares and institutions hold larger chunk of about 51.47% of that.
The stock has a current market capitalization of $58.36M and its 3Y-monthly beta is at 1.17. It has posted earnings per share of -$1.66 in the same period. It has Quick Ratio of 6.04 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ACHL, volatility over the week remained 1.52% while standing at 1.37% over the month.
Stock’s fiscal year EPS is expected to rise by 89.66% while it is estimated to increase by 33.33% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on April 05, 2024 offering a Neutral rating for the stock and assigned a target price range of between $8 and $2 to it. Coverage by Piper Sandler stated Achilles Therapeutics Plc ADR (ACHL) stock as an Overweight in their note to investors on April 26, 2021, suggesting a price target of $25 for the stock. On April 26, 2021, Oppenheimer Initiated their recommendations, while on April 26, 2021, JP Morgan Initiated their ratings for the stock with a price target of $11. Stock get a Buy rating from Chardan Capital Markets on April 26, 2021.
